{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:58:56Z","timestamp":1792504736087,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA098838"],"award-info":[{"award-number":["R01 CA098838"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01AG032249"],"award-info":[{"award-number":["R01AG032249"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24 CA1715"],"award-info":[{"award-number":["U24 CA1715"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11764-018-0716-6","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T10:57:03Z","timestamp":1539860223000},"page":"794-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-7162","authenticated-orcid":false,"given":"Matthew P.","family":"Banegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyce S.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninah S.","family":"Achacoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Alexeeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Habel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"716_CR1","volume-title":"Cancer facts & figures 2018","author":"American Cancer Society","year":"2018","unstructured":"American Cancer Society. Cancer facts & figures 2018. Atlanta, GA: American Cancer Society; 2018."},{"issue":"9","key":"716_CR2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290\u2013314.","journal-title":"Cancer"},{"issue":"4","key":"716_CR3","first-page":"41","volume":"29","author":"AW Smith","year":"2008","unstructured":"Smith AW, Reeve BB, Bellizzi KM, Harlan LC, Klabunde CN, Amsellem M, et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev. 2008;29(4):41\u201356.","journal-title":"Health Care Financ Rev"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"206414","DOI":"10.1155\/2012\/206414","volume":"2012","author":"L Deckx","year":"2012","unstructured":"Deckx L, et al. Chronic diseases among older cancer survivors. J Cancer Epidemiol. 2012;2012:206414.","journal-title":"J Cancer Epidemiol"},{"issue":"8","key":"716_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinte.167.8.781","volume":"167","author":"SN Hilmer","year":"2007","unstructured":"Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781\u20137.","journal-title":"Arch Intern Med"},{"issue":"5","key":"716_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-010-0813-1","volume":"18","author":"J Cashman","year":"2010","unstructured":"Cashman J, Wright J, Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18(5):651\u20135.","journal-title":"Support Care Cancer"},{"issue":"6","key":"716_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1200\/JOP.2011.000460","volume":"7","author":"CS Ritchie","year":"2011","unstructured":"Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7(6):371\u20134.","journal-title":"J Oncol Pract"},{"issue":"6","key":"716_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1200\/JOP.2014.003046","volume":"11","author":"BC Stuart","year":"2015","unstructured":"Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a diagnosis of cancer among Medicare beneficiaries with diabetes. J Oncol Pract. 2015;11(6):429\u201334.","journal-title":"J Oncol Pract"},{"issue":"1","key":"716_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-013-2424-2","volume":"138","author":"GS Calip","year":"2013","unstructured":"Calip GS, Boudreau DM, Loggers ET. Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat. 2013;138(1):225\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"716_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/pds.3660","volume":"24","author":"GS Calip","year":"2014","unstructured":"Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf. 2014;24(1):75\u201385.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"716_CR11","doi-asserted-by":"publisher","first-page":"e800","DOI":"10.1200\/JOP.2016.011742","volume":"12","author":"J Yang","year":"2016","unstructured":"Yang J, Neugut AI, Wright JD, Accordino M, Hershman DL. Nonadherence to oral medications for chronic conditions in breast cancer survivors. J Oncol Pract. 2016;12(8):e800\u20139.","journal-title":"J Oncol Pract"},{"issue":"6","key":"716_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/pds.4198","volume":"26","author":"YT Chou","year":"2017","unstructured":"Chou YT, Winn AN, Rosenstein DL, Dusetzina SB. Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiol Drug Saf. 2017;26(6):676\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"716_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1007\/s11606-007-0385-z","volume":"22","author":"WF Gellad","year":"2007","unstructured":"Gellad WF, Haas JS, Safran DG. Race\/ethnicity and nonadherence to prescription medications among seniors: results of a national study. J Gen Intern Med. 2007;22(11):1572\u20138.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"716_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1345\/aph.1L368","volume":"43","author":"I Poon","year":"2009","unstructured":"Poon I, Lal LS, Ford ME, Braun UK. Racial\/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother. 2009;43(2):185\u201393.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"716_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2337\/dc07-1924","volume":"31","author":"AS Adams","year":"2008","unstructured":"Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, et al. Medication adherence and racial differences in A1C control. Diabetes Care. 2008;31(5):916\u201321.","journal-title":"Diabetes Care"},{"issue":"4","key":"716_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11606-013-2692-x","volume":"29","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Baik SH. Race\/ethnicity, disability, and medication adherence among Medicare beneficiaries with heart failure. J Gen Intern Med. 2014;29(4):602\u20137.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"716_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/2013.jamainternmed.955","volume":"173","author":"AS Adams","year":"2013","unstructured":"Adams AS, Uratsu C, Dyer W, Magid D, O\u2019Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2013;173(1):54\u201361.","journal-title":"JAMA Intern Med"},{"issue":"9326","key":"716_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative, G","year":"2002","unstructured":"Heart Protection Study Collaborative, G. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"key":"716_CR19","doi-asserted-by":"crossref","unstructured":"Taylor F, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816.","DOI":"10.1002\/14651858.CD004816.pub5"},{"issue":"19","key":"716_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008\u201324.","journal-title":"JAMA"},{"issue":"19","key":"716_CR21","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345.","journal-title":"JAMA"},{"issue":"9346","key":"716_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623\u201330.","journal-title":"Lancet"},{"issue":"18","key":"716_CR23","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1517\/14656560903376186","volume":"10","author":"TR Bates","year":"2009","unstructured":"Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973\u201385.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"716_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1074248415578170","volume":"20","author":"A Turin","year":"2015","unstructured":"Turin A, Pandit J, Stone NJ. Statins and nonadherence: should we RELATE better? J Cardiovasc Pharmacol Ther. 2015;20(5):447\u201356.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"716_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cjca.2012.03.018","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, Blackburn D. Nonadherence to statin therapy: discontinuation after a single fill. Can J Cardiol. 2012;28(5):567\u201373.","journal-title":"Can J Cardiol"},{"issue":"5","key":"716_CR26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574\u201380.","journal-title":"Can J Cardiol"},{"issue":"4","key":"716_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455\u201361.","journal-title":"JAMA"},{"issue":"6","key":"716_CR28","first-page":"388","volume":"14","author":"S Vinker","year":"2008","unstructured":"Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388\u201392.","journal-title":"Am J Manag Care"},{"key":"716_CR29","volume-title":"Northern California cancer registry: 2015 annual report on trends, incidence, and outcomes","author":"MD Oehrli","year":"2015","unstructured":"Oehrli MD, Quesenberry CP. Northern California cancer registry: 2015 annual report on trends, incidence, and outcomes. Oakland, CA: Kaiser Permanente; 2015."},{"key":"716_CR30","unstructured":"Nau DP. Proportion of days covered (PDC) as the preferred method of measuring medication adherence. 02\/01\/2016]; Available from: www.pqaalliance.org\/images\/uploads\/files\/PQA%20PDC%20vs%20%20MPR.pdf ."},{"issue":"4","key":"716_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1524-4733.2008.00474.x","volume":"12","author":"MB Nichol","year":"2009","unstructured":"Nichol MB, Knight TK, Wu J, Tang SSK, Cherry SB, Benner JS, et al. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health. 2009;12(4):544\u201350.","journal-title":"Value Health"},{"issue":"1","key":"716_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18553\/jmcp.2014.20.1.51","volume":"20","author":"JF Slejko","year":"2014","unstructured":"Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51\u20137.","journal-title":"J Manag Care Pharm"},{"key":"716_CR33","volume-title":"Applied longitudinal analysis","year":"2011","unstructured":"Fitzmaurice GM, Laird NM, Ware JH, editors. Applied longitudinal analysis. Second ed. New York, New York: John Wiley and Sons; 2011.","edition":"Second ed"},{"issue":"4","key":"716_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","volume":"66","author":"D Sarfati","year":"2016","unstructured":"Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337\u201350.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"716_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00520-009-0802-4","volume":"19","author":"DW Shin","year":"2010","unstructured":"Shin DW, Park JH, Park JH, Park EC, Kim SY, Kim SG, et al. Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study. Support Care Cancer. 2010;19(2):211\u201320.","journal-title":"Support Care Cancer"},{"issue":"9","key":"716_CR36","first-page":"1052","volume":"22","author":"J Tam-McDevitt","year":"2008","unstructured":"Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park). 2008;22(9):1052\u20135 discussion 1055, 1058, 1060.","journal-title":"Oncology (Williston Park)"},{"issue":"7","key":"716_CR37","first-page":"386","volume":"7","author":"M daCosta DiBonaventura","year":"2014","unstructured":"daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits. 2014;7(7):386\u201396.","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"716_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jnci\/djk130","volume":"99","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592\u2013600.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"716_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jpainsymman.2007.06.009","volume":"35","author":"RP Riechelmann","year":"2008","unstructured":"Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35(5):535\u201343.","journal-title":"J Pain Symptom Manag"},{"issue":"12","key":"716_CR40","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","volume":"20","author":"RP Riechelmann","year":"2009","unstructured":"Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20(12):1907\u201312.","journal-title":"Ann Oncol"},{"issue":"8","key":"716_CR41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","volume":"5","author":"JH Beijnen","year":"2004","unstructured":"Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489\u201396.","journal-title":"Lancet Oncol"},{"issue":"2","key":"716_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.critrevonc.2005.03.007","volume":"55","author":"P Blower","year":"2005","unstructured":"Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55(2):117\u201342.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"716_CR43","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","volume":"16","author":"TW LeBlanc","year":"2015","unstructured":"LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16(7):e333\u201341.","journal-title":"Lancet Oncol"},{"key":"716_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/VHRM.S56056","volume":"10","author":"J Gatwood","year":"2014","unstructured":"Gatwood J, Bailey JE. Improving medication adherence in hypercholesterolemia: challenges and solutions. Vasc Health Risk Manag. 2014;10:615\u201325.","journal-title":"Vasc Health Risk Manag"},{"issue":"20","key":"716_CR45","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1200\/JCO.2018.77.7482","volume":"36","author":"PB Jacobsen","year":"2018","unstructured":"Jacobsen PB, DeRosa AP, Henderson TO, Mayer DK, Moskowitz CS, Paskett ED, et al. Systematic review of the impact of cancer survivorship care plans on health outcomes and health care delivery. J Clin Oncol. 2018;36(20):2088\u2013100.","journal-title":"J Clin Oncol"},{"issue":"8","key":"716_CR46","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.30560","volume":"123","author":"Z Zheng","year":"2017","unstructured":"Zheng Z, Han X, Guy GP Jr, Davidoff AJ, Li C, Banegas MP, et al. Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. Cancer. 2017;123(8):1453\u201363.","journal-title":"Cancer"},{"issue":"6","key":"716_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6):481\u201396.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"716_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306\u201311.","journal-title":"J Clin Oncol"},{"issue":"14","key":"716_CR49","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.30648","volume":"123","author":"S Kaul","year":"2017","unstructured":"Kaul S, Avila JC, Mehta HB, Rodriguez AM, Kuo YF, Kirchhoff AC. Cost-related medication nonadherence among adolescent and young adult cancer survivors. Cancer. 2017;123(14):2726\u201334.","journal-title":"Cancer"},{"issue":"8","key":"716_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/MLR.0000000000000159","volume":"52","author":"AS Adams","year":"2014","unstructured":"Adams AS, Madden JM, Zhang F, Soumerai SB, Gilden D, Griggs J, et al. Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Med Care. 2014;52(8):695\u2013703.","journal-title":"Med Care"},{"issue":"9","key":"716_CR51","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1345\/aph.1P150","volume":"44","author":"DM Mann","year":"2010","unstructured":"Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410\u201321.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"716_CR52","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.clinthera.2009.10.002","volume":"31","author":"Y Yang","year":"2009","unstructured":"Yang Y, Thumula V, Pace PF, Banahan BF III, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009;31(10):2178\u201388 discussion 2150-1.","journal-title":"Clin Ther"},{"issue":"2","key":"716_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2013.1113","volume":"11","author":"SJ Rolnick","year":"2013","unstructured":"Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54\u201365.","journal-title":"Clin Med Res"},{"issue":"36","key":"716_CR54","doi-asserted-by":"publisher","first-page":"967","DOI":"10.15585\/mmwr.mm6536e1","volume":"65","author":"M Ritchey","year":"2016","unstructured":"Ritchey M, Chang A, Powers C, Loustalot F, Schieb L, Ketcham M, et al. Vital signs: disparities in antihypertensive medication nonadherence among Medicare part D beneficiaries - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(36):967\u201376.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"716_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-016-4043-1","volume":"161","author":"GS Calip","year":"2017","unstructured":"Calip GS, Elmore JG, Boudreau DM. Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors. Breast Cancer Res Treat. 2017;161(1):161\u201372.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"716_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","volume":"175","author":"G Danaei","year":"2012","unstructured":"Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250\u201362.","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11764-018-0716-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-018-0716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-018-0716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T05:42:48Z","timestamp":1662270168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11764-018-0716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1007\/s11764-018-0716-6","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"17 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MPB has received research grants from AstraZeneca, and LAH has received research grants from Genentech, for projects outside of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was a secondary analysis of existing dataset with no PHI and, therefore, did not meet the definition of human subject research. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}